Nadia Zaffaroni

Optimization of a Subcutaneous Epithelioid Hemangioendothelioma Xenograft Model for Evaluation of Preclinical Therapeutics

This study optimizes a subcutaneous xenograft model for EHE using patient-derived cells, showing that low cell densities produce reproducible tumors sensitive to mTOR inhibition.

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

This paper identifies HDAC inhibition as a strategy to overcome resistance to EZH2 inhibitors in INI1-deficient epithelioid sarcoma by restoring H3K27 acetylation and enhancing therapeutic response.

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.